author-photo

M. J. Piccart

44

Papers

289

Citations

Citation Trend

Filter By

Papers (32) Sort By

Journal Conference Others

266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
131P Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
?Bridge? neoadjuvant endocrinetherapy for early stage breast cancer patients during COVID-19 at an academic hospital in NYC: Lessonslearned

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)